PolyPid Announces Participation in Upcoming Fall Investor Conferences

PolyPid schedules multiple fall 2026 conferences, giving investors live and virtual access to management and its pipeline story.

Rhea-AI Summary

PolyPid (PYPD) will participate in three investor conferences in fall 2026, offering panel appearances, company presentations, and one-on-one investor meetings.

Events include the 5th Annual ROTH Healthcare Opportunities Conference at the Metropolitan Club in New York on September 29, 2026; the Lytham Partners Fall 2026 Investor Conference with a webcasted presentation on September 29 and virtual 1-on-1 meetings on September 30; and the Craig-Hallum 17th Annual Alpha Select Conference at the Sheraton New York Times Square Hotel on November 17, 2026. PolyPid develops long-acting, controlled-release drugs and reports that lead product D-PLEX100 met primary and key secondary endpoints in the Phase 3 SHIELD II trial.

Key Terms

phase 3, controlled-release, primary endpoint, secondary endpoints

4 terms

phase 3 medical

"The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

controlled-release technical

"The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care"

A controlled-release medicine is a drug formulation designed to release its active ingredient gradually over a set period instead of all at once. Like a slow-drip faucet that keeps a steady flow rather than a single pour, it helps maintain more stable drug levels in the body, which can affect dosing schedules, patient adherence, manufacturing complexity, regulatory review, patent life, and potential market value for companies that make or sell the product.

primary endpoint medical

"D-PLEX100, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial"

The primary endpoint is the single main result a clinical study is designed to measure to decide if a treatment works, like the finish line in a race that tells you who won. Investors care because meeting or missing this goal drives regulatory decisions, future sales expectations and stock value — it turns trial data into a clear yes-or-no signal about a drug’s commercial prospects.

secondary endpoints medical

"successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial"

Secondary endpoints are the additional outcomes measured in a clinical study beyond the main goal; they can include effects on symptoms, quality of life, safety measures, or other health indicators. For investors, they matter because positive or negative secondary results can strengthen or weaken the overall story about a treatment’s benefits and risks—like seeing not only that a car reaches its destination (primary goal) but also how comfortable and efficient the ride was (secondary findings).

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PETACH TIKVA, Israel, Sept. 15, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), an innovative biopharmaceutical company dedicated to improving patient outcomes by elevating treatment effectiveness, right where care begins, today announced that senior management will participate in the following upcoming investor conferences:

5th Annual ROTH Healthcare Opportunities Conference
Dates: September 29, 2026
Location: Metropolitan Club, New York, NY
Format: Panel discussion and one-on-one investor meetings
Panel: “The Biotech Reset: Regulatory Uncertainty, Capital Constraints and the Search for Value,” 12:00-12:30 p.m. ET

Investors interested in meeting with PolyPid should contact their ROTH representative directly.

Lytham Partners Fall 2026 Investor Conference
Company Presentation: September 29, 2026 at 12:15 p.m. ET. A replay will be available following the event.
1-on-1 Investor meetings: September 30, 2026
Location: Virtual
Format: Webcast presentation and one-on-one investor meetings.
Webcast registration: https://app.webinar.net/oXx0aBZaQVv.

Investors interested in meeting with PolyPid should contact Lytham Partners at 1x1@lythampartners.com.

Craig-Hallum 17th Annual Alpha Select Conference
Date: November 17, 2026
Location: The Sheraton New York Times Square Hotel, New York, NY
Format: One-on-one investor meetings

Investors interested in meeting with PolyPid should contact their Craig-Hallum representative directly.

About PolyPid
PolyPid Ltd. (Nasdaq: PYPD) is an innovative biopharmaceutical company dedicated to elevating treatment effectiveness, right where care begins. The Company develops long-acting, controlled-release drugs designed to deliver therapy precisely at the site of care, addressing critical unmet medical needs across a wide and diverse pipeline spanning surgical care, metabolic diseases, and beyond. PolyPid’s lead product, D-PLEX₁₀₀, successfully met its primary and all key secondary endpoints in the landmark Phase 3 SHIELD II trial for the prevention of surgical site infections. Guided by a commitment to precision and innovation, PolyPid is redefining how therapies perform and raise the standard of patient care. For additional Company information, please visit http://www.polypid.com and follow us on Twitter (X) and LinkedIn.

Company Contact:
PolyPid Ltd.
Ori Warshavsky
908-858-5995
IR@Polypid.com

Investor Relations Contact:
Arx Investor Relations
North American Equities Desk
polypid@arxhq.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How can investors access PolyPid's presentation at the Lytham Partners Fall 2026 Investor Conference?

PolyPid's company presentation at the Lytham Partners Fall 2026 Investor Conference is scheduled for September 29, 2026 at 12:15 p.m. ET. The format is a webcast presentation, and a replay will be available following the event. Webcast registration is available at https://app.webinar.net/oXx0aBZaQVv.

How can investors arrange one-on-one meetings with PolyPid during these conferences?

For the ROTH Healthcare Opportunities Conference and the Craig-Hallum 17th Annual Alpha Select Conference, investors interested in meeting with PolyPid should contact their respective ROTH or Craig-Hallum representatives directly. For the Lytham Partners Fall 2026 Investor Conference, investors should email 1x1@lythampartners.com to request one-on-one meetings on September 30, 2026.

What is PolyPid's lead product and current clinical status as described?

PolyPid identifies D-PLEX100 as its lead product. The company states that D-PLEX100 successfully met its primary and all key secondary endpoints in the Phase 3 SHIELD II trial, which evaluated prevention of surgical site infections.